10X Genomics (TXG) PT Lowered to $60 at Morgan Stanley
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
Tweet
Share
E-mailGet Alerts TXG Hot Sheet
Price: $65.29 --0%
Rating Summary:
7 Buy, 13 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 17 | New: 12
Rating Summary:
7 Buy, 13 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 17 | New: 12
Join SI Premium – FREE
Morgan Stanley analyst Tejas Savant lowered the price target on 10X Genomics (NASDAQ: TXG) to $60.00 (from $65.00) while maintaining a Overweight rating.
You May Also Be Interested In
- 10x Genomics launches AI-powered single cell analysis tool
- Red Rock Resorts (RRR) PT Lowered to $64 at Susquehanna
- Chaozhou Three-Circle Group Co Ltd (300408:CH) PT Lowered to RMB124 at Nomura/Instinet
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
